UY26969A1 - Combinaciones farmacéuticas - Google Patents

Combinaciones farmacéuticas

Info

Publication number
UY26969A1
UY26969A1 UY26969A UY26969A UY26969A1 UY 26969 A1 UY26969 A1 UY 26969A1 UY 26969 A UY26969 A UY 26969A UY 26969 A UY26969 A UY 26969A UY 26969 A1 UY26969 A1 UY 26969A1
Authority
UY
Uruguay
Prior art keywords
pharmaceutical combinations
nif
thrombolytic
neuroprotective
favors
Prior art date
Application number
UY26969A
Other languages
English (en)
Inventor
Christopher John Brearley
Paul Butler
Suresh Babubhai Chahwala
Michael Chopp
Michael Krams
Michael Looby
Fiona Macintyre
Andrew Brian Mcelroy
Aileen Dorothy Mcharg
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of UY26969A1 publication Critical patent/UY26969A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Esta invención se refiere, entre otros, a métodos para tratar condiciones patofisiológicas que implican a los neutrófilos, que comprenden administrar a un paciente que necesite tal tratamiento una terapia de combinación que comprende al menos un factor inhibidor de los neutrófilos (NIF) y al menos otro agente que protege a las neuronas de la agresión tóxica, inhibe la reacción inflamatoria después de una lesión cerebral o favorece la reperfusión cerebral (esto es, agentes neuroprotectores o trombolíticos/fibrinolíticos), o una serie de sus sales farmacéuticamente aceptables.
UY26969A 2000-10-17 2001-10-16 Combinaciones farmacéuticas UY26969A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0025473.0A GB0025473D0 (en) 2000-10-17 2000-10-17 Pharmaceutical combinations

Publications (1)

Publication Number Publication Date
UY26969A1 true UY26969A1 (es) 2002-06-20

Family

ID=9901490

Family Applications (1)

Application Number Title Priority Date Filing Date
UY26969A UY26969A1 (es) 2000-10-17 2001-10-16 Combinaciones farmacéuticas

Country Status (13)

Country Link
US (1) US20020098179A1 (es)
AP (1) AP2001002295A0 (es)
AR (1) AR034698A1 (es)
AU (1) AU2002210795A1 (es)
DO (1) DOP2001000266A (es)
GB (1) GB0025473D0 (es)
GT (1) GT200100207A (es)
HN (1) HN2001000232A (es)
PA (1) PA8530701A1 (es)
PE (1) PE20020536A1 (es)
TN (1) TNSN01142A1 (es)
UY (1) UY26969A1 (es)
WO (1) WO2002032446A2 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10153601A1 (de) * 2001-11-02 2003-05-22 Paion Gmbh DSPA zur Behandlung von Schlaganfall
US20030219431A1 (en) * 2002-05-24 2003-11-27 Empire Pharmaceuticals, Inc. Treatment of neuronal and neurological damage associated with spinal cord injury
CN1310949C (zh) * 2003-01-13 2007-04-18 重庆富进生物医药有限公司 具有抑制白细胞功能和凝血酶活性的双功能嵌合蛋白
CA2426115A1 (en) * 2003-04-18 2004-10-18 Victor Gurewich Methods, devices, and compositions for lysis of occlusive blood clots while sparing wound sealing clots
DE602005020462D1 (de) 2004-08-25 2010-05-20 Essentialis Inc Pharmazeutische formulierungen von kalium-atp-kanalöffnern und deren verwendungen
WO2006094120A2 (en) * 2005-03-02 2006-09-08 The Regents Of The University Of California Treatment for embolic stroke
US20070166299A1 (en) * 2005-03-02 2007-07-19 The Regents Of The University Of California Treatment for embolic stroke
US20070167419A1 (en) * 2005-03-02 2007-07-19 The Regents Of The University Of California Treatment for embolic stroke
EP3545958A1 (en) 2006-01-05 2019-10-02 Essentialis, Inc. Salts of potassium atp channel openers and uses thereof
CN101245110B (zh) * 2007-02-16 2010-09-15 鲁南制药集团股份有限公司 重组中性粒细胞抑制因子和水蛭原嵌合蛋白及其药物组合物
AU2008272923A1 (en) * 2007-07-02 2009-01-08 Essentialis, Inc. Salts of potassium ATP channel openers and uses thereof
AR068914A1 (es) * 2007-10-18 2009-12-16 Paion Deutschland Gmbh Uso de un activador de plasminogeno para la preparacion de un medicamento para el tratamiento de apoplejia
CN102458441A (zh) 2009-06-10 2012-05-16 诺诺公司 用于治疗神经疾病的模型系统和治疗方案
DK2723363T3 (en) * 2011-06-24 2018-10-15 Nono Inc COMBINATION THERAPY AGAINST CREAM
US9241970B2 (en) 2011-12-13 2016-01-26 Nono Inc. Therapy for subarachnoid hemorrhage and ischemia
JP6826040B2 (ja) 2014-11-03 2021-02-03 スロンボリティック・サイエンス・リミテッド・ライアビリティ・カンパニーＴｈｒｏｍｂｏｌｙｔｉｃ Ｓｃｉｅｎｃｅ， Ｌｌｃ 安全かつ効果的な血栓溶解（Ｔｈｒｏｍｂｏｌｙｓｉｓ）のための方法および組成物
US10336827B2 (en) 2015-10-29 2019-07-02 Wayne State University Compositions and methods to treat solid tumors
US11154596B2 (en) 2017-06-16 2021-10-26 Thrombolytic Science, Llc Methods for thrombolysis
WO2022261282A1 (en) * 2021-06-09 2022-12-15 Proniras Corporation Methods of treating or preventing conditions associated with opiate withdrawal or opiate relapse

Also Published As

Publication number Publication date
HN2001000232A (es) 2002-04-22
AR034698A1 (es) 2004-03-17
TNSN01142A1 (fr) 2005-11-10
AP2001002295A0 (en) 2001-12-31
PA8530701A1 (es) 2003-06-30
GT200100207A (es) 2002-08-19
WO2002032446A2 (en) 2002-04-25
AU2002210795A1 (en) 2002-04-29
GB0025473D0 (en) 2000-11-29
WO2002032446A3 (en) 2002-07-11
US20020098179A1 (en) 2002-07-25
DOP2001000266A (es) 2002-05-31
PE20020536A1 (es) 2002-06-20

Similar Documents

Publication Publication Date Title
UY26969A1 (es) Combinaciones farmacéuticas
AR012671A1 (es) Composiciones farmaceuticas para el tratamiento o profilaxis de la constipacion, los usos de dichas composiciones y los procesos para prepararlos
AR035533A1 (es) Uso de por lo menos un inhibidor de la absorcion de los esteroles o sus sales, solvatos, prodrogas farmaceuticamente aceptables o mezclas de los mismos para la preparacion de un medicamento para el tratamiento de la sitosterolemia, composiciones farmaceuticas, el uso de dichas composiciones para la
PA8606201A1 (es) DERIVADOS DE PIRROLO[3,4-c) PIRAZOL ACTIVOS COMO INHIBIDORES DE QUINASA, PROCESO PARA SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN
NO20024814D0 (no) Terapeutiske kombinasjoner av antihypertensive og antiangiogene midler
AR038535A1 (es) Formulaciones farmaceuticas de agentes antineoplasicos y procesos para prepararlos y usarlos
HUP0203160A2 (hu) Plakk ruptura kialakulásának megakadályozása ACAT-inhibitorok alkalmazásával
ECSP066516A (es) Formulaciones farmacéuticas, procedimientos y pautas de dosificación para el tratamiento y prevención de síndromes coronarios agudos
NO20012896L (no) Fremgangsmåte for behandling av cerebral ischemi og anvendelse av erytropoietin eller erytropoietinderivater forbehandling av cerebral ischemi
ES2185816T3 (es) Formas de dosificacion farmaceutica para la via oral, que comprenden un agente inhibidor de la bomba de protones y un agente procinetico.
MXPA03008623A (es) Combinacion farmaceutica para el tratamiento del cancer.
MY119375A (en) Treatment of tinnitus using neuroprotective agents
TR200101120T2 (tr) Serin proteaz inhibitörü
ES2154693T3 (es) Combinacion de sustancias inductoras de necrosis con sustancias que son activadas por necrosis, para la terapia selectiva de tumores y enfermedades inflamatorias.
CO5590913A2 (es) Terapia de combinacion antivirica
AR034343A1 (es) Combinaciones farmaceuticas
CY1119190T1 (el) Χρηση αναστολεων της il-18 για αγωγη ή προληψη βλαβων του κνς
BR0117009A (pt) Composiçoes para utilização no tratamento de distúrbios associados a ige
ES2180933T3 (es) Inhibidor de la serina-proteasa.
NO20061184L (no) Fremgangsmater og blandinger for behandling av herpes-infeksjoner
PL368971A1 (en) Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate
ES2165034T3 (es) Agentes terapeuticos que contienen ebselen contra el asma.
ES2155223T3 (es) 1-naftoilguanidinas sustituidas, procedimiento para su preparacion, su empleo como medicamento o agente de diagnostico, asi como medicamento que las contiene.
MXPA04001268A (es) Inhibidor de anhidrasa carbonica.
MX9305106A (es) Metodos para el tratamiento de cancer.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150424